Fuso Pharmaceutical Industries,Ltd.
Tokyo Stock ExchangeTotal Valuation
Fuso Pharmaceutical Industries,Ltd. carries a market capitalization of 18.31B, placing it among publicly traded companies globally. Its enterprise value stands at 28.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.31B |
| Enterprise Value | 28.36B |
Share Statistics
Fuso Pharmaceutical Industries,Ltd. currently has 8.54M shares outstanding.
| Shares Outstanding | 8.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Fuso Pharmaceutical Industries,Ltd. trades at a trailing price-to-earnings ratio of 29.06. The price-to-sales ratio is 0.69, and the price-to-book ratio stands at 0.67.
| PE Ratio | 29.06 |
| PS Ratio | 0.69 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Fuso Pharmaceutical Industries,Ltd. trades at an EV/EBITDA multiple of 32.79 and an EV/FCF ratio of 353.78. The EV/Sales ratio of 1.01 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.79 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.01 |
| EV / EBITDA | 32.79 |
| EV / EBIT | 32.79 |
| EV / FCF | 353.78 |
Financial Position
Fuso Pharmaceutical Industries,Ltd. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.42, indicating elevated leverage, while an interest coverage ratio of 9.61 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.37 |
| Quick Ratio | 0.14 |
| Debt / Equity | 36.42 |
| Debt / EBITDA | 15.96 |
| Interest Coverage | 9.61 |
Financial Efficiency
Fuso Pharmaceutical Industries,Ltd. posts a return on equity of 2.38 and a return on invested capital of 1.51.
| Return on Equity (ROE) | 2.38 |
| Return on Assets (ROA) | 0.87 |
| Return on Invested Capital (ROIC) | 1.51 |
| Return on Capital Employed (ROCE) | 1.78 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.52 |
Taxes
Over the trailing twelve months, Fuso Pharmaceutical Industries,Ltd. has paid 81.00M in income taxes, reflecting an effective tax rate of 10.92.
| Income Tax | 81.00M |
| Effective Tax Rate | 10.92 |
Stock Price Statistics
Fuso Pharmaceutical Industries,Ltd.'s stock has gained approximately 2.72989% over the past 52 weeks. The 50-day moving average sits at 2,094.38, while the 200-day moving average is 2,233.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.72989% |
| 50-Day Moving Average | 2,094.38 |
| 200-Day Moving Average | 2,233.13 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Fuso Pharmaceutical Industries,Ltd. generated 27.98B in revenue and converted that into 660.00M in net income, yielding earnings per share of 77.45. EBITDA reached 865.00M, while operating income came in at 865.00M.
| Revenue | 27.98B |
| Gross Profit | 6.96B |
| Operating Income | 865.00M |
| Pretax Income | 742.00M |
| Net Income | 660.00M |
| EBITDA | 865.00M |
| EBIT | 865.00M |
| Earnings Per Share (EPS) | 77.45 |
Balance Sheet
Fuso Pharmaceutical Industries,Ltd. holds 4.62B in cash and equivalents against 13.80B in total debt, resulting in a net debt position of 9.19B. Total book value stands at 28.54B, with working capital of 12.30B providing operational flexibility.
| Cash & Cash Equivalents | 4.62B |
| Total Debt | 13.80B |
| Net Debt | 9.19B |
| Equity (Book Value) | 28.54B |
| Book Value Per Share | 3,343.50 |
| Working Capital | 12.30B |
Margins
Fuso Pharmaceutical Industries,Ltd. operates with a gross margin of 24.88, reflecting its pricing power and cost economics. The operating margin of 3.09 and net profit margin of 2.36 provide insight into operational efficiency.
| Gross Margin | 24.88 |
| Operating Margin | 3.09 |
| Pretax Margin | 2.65 |
| Profit Margin | 2.36 |
| EBITDA Margin | 3.09 |
Stock Splits
Fuso Pharmaceutical Industries,Ltd.'s most recent stock split took place on September 28, 2016 with a 10:1 split ratio.
| Last Split Date | 9/28/2016 |
| Split Ratio | 10:1 |
Scores
Fuso Pharmaceutical Industries,Ltd. posts an Altman Z-Score of 1.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.24 |